Information Technology · Miscellaneous Electrical Machinery, Equipment & Supplies

NOVT NOVANTA INC SEC Filings & Insider Trading Activity 2026

company
CIK 1076930137 filings
Russell 2000

NOVT at a glance

NOVANTA INC (NOVT, SEC CIK 1076930) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), NOVANTA INC (NOVT) reported revenue of $980.6 million (up 3.3% from FY2024) and net income of $53.8 million. Diluted EPS was $1.47.
  • As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding NOVANTA INC (NOVT) shares worth $2.6 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Secor Thomas N on September 11, 2026 of 663 shares at $147.60 per share.
  • In the last 90 days, NOVT insiders reported 0 open-market purchases ($0) and 1 open-market sale ($98K) on Form 4, a net sale of $98K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$980.6M
+3.3% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$98K
13F holders
33 funds
$2.6B · −3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Supplier of proprietary technology solutions for medical, life science, and advanced industrial OEMs focused on precision and performance
  • New emphasis on RFID solutions through acquisition of Keonn Technologies for €64.8M ($71.0M), included in Medical Solutions segment
  • Strategic shift: Increased focus on growing medical sales percentage, targeting minimally invasive and robotic surgery, ophthalmology, and life science applications
  • Key metric: Consolidated backlog increased to $481.2M from $445.5M, signaling stronger demand pipeline
  • Noteworthy event: Issued 12.65M tangible equity units raising net proceeds of $613.1M for growth and capital deployment

Risk Factors

  • Regulatory/legal risk: Restrictions on dividends and asset transfers from foreign subsidiaries under local laws impacting funding for parent operations
  • Geopolitical/macro risk: $67.6M cash and $74M debt held by non-North American subsidiaries, limiting capital repatriation flexibility
  • Operational/supply chain risk: Higher inventory levels due to regionalized manufacturing strategy reducing 2025 operating cash flow to $64.1M from $158.5M in 2024
  • Competitive/market disruption risk: Share repurchase plans open to market fluctuations, with $200M authorization in 2025 but no repurchases yet, risking shareholder dilution management
  • Financial/structural risk: $632.5M tangible equity units issued with $110.6M amortizing notes outstanding, bearing 6.30% interest and $33.6M estimated future interest on senior credit facilities

AI summary of the NOVT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Oct 2, 2026

Risk Factors

  • Newly added geopolitical risk: February 2026 U.S.-Israel-Iran conflict increased energy, freight and commodity costs
  • Most material acquisition risk: Riverpoint Medical purchase for $1,200.6 million heightened integration and impairment exposure
  • Regulatory risk: Chinese export-license restrictions delayed rare-earth material shipments and customer order fulfillment
  • Operational risk: Limited or single-source components could cause missed shipments and permanent customer-order losses
  • Financial risk: Total debt increased to $838.6 million as of October 2, 2026, raising variable-rate exposure

Management Discussion & Analysis

  • Revenue $305.0M, up $57.2M or 23.1% YoY, including $32.9M from the 2026 acquisition
  • Total gross margin 44.5% vs 44.8% YoY, operating margin 4.6% vs 8.8% YoY
  • Best segment Automation Enabling Technologies: revenue $145.4M, up 16.0%, operating margin 28.1% vs 21.8%
  • Worst segment Medical Solutions margin: operating margin 6.0% vs 13.0%, gross margin 39.9% vs 43.0%
  • Cash $149.2M vs $380.9M, operating cash flow $155.9M, acquisition investment $1,200.6M, 2026 capex outlook $30M to $40M

AI summary of the NOVT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Novanta announced fiscal Q3 2026 financial results for the quarter ended October 2, 2026
  • Investor-relevant revenue, earnings and outlook details are in Exhibit 99.1, the accompanying earnings release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $305.0M, up 23.1%, with 9.9% organic growth and $32.9M acquisition contribution
  • Adjusted EBITDA $80.3M, up 38.3%, margin 26.3% versus 23.4%, signaling operating leverage
Filed Oct 2, 2026Full analysis →

Item EX-99.3: Item EX-99.3

  • Transaction closed July 23, 2026 for $1,450.6M, including $244.1M fair-valued milestone payable by January 8, 2027
  • Funding included $616.0M debt and $287.6M net equity proceeds, materially increasing leverage and share count

Item EX-99.1: Item EX-99.1

  • Audited 2025 financials for Riverpoint Medical, the business owned by Runway Buyer, LLC, support SEC acquisition-reporting requirements
  • Revenue $136.1M and net income $11.5M, indicating a profitable medical-device target

Item EX-99.2: Item EX-99.2

  • Runway Buyer generated $33.5M revenue and $2.4M net income in Q1 2026
  • Operating income $7.5M, offset by $4.5M interest expense and 20.8% effective tax rate
Filed Aug 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Fiscal quarter ended July 3, 2026 results announced
  • Novanta’s press release contains the financial performance details investors need

Item EX-99.1: Item EX-99.1

  • Q2 revenue rose 10.3% to $265.8M, with organic growth of 9.3%, indicating broad-based underlying demand
  • Adjusted EBITDA increased 16.4% to $60.7M, expanding margin to 22.8% from 21.6%

AI summaries of NOVT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for NOVT

Don't miss the next NOVT filing

  • Alerts as it files. A push when NOVT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut NOVT, by share count.
  • Ask anything. An AI agent that reads every NOVT filing and answers with sources.

NOVT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
FARRELL MATTHEWMNov 3, 2026-
FARRELL MATTHEWMNov 3, 2026-
Secor Thomas NSellSep 11, 2026$147.60
Glastra MatthijsSellJul 2, 2026$163.71
Glastra MatthijsSellJul 2, 2026$162.01
Glastra MatthijsSellJul 2, 2026$162.01
Glastra MatthijsSellJul 2, 2026$160.13
Glastra MatthijsSellJul 2, 2026$163.71

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$949.2M$980.6M
Gross Profit-$421.5M$435.3M
Operating Income-$110.6M$94.0M
Net Income-$64.1M$53.8M
Gross Margin-44.4%44.4%
Op. Margin-11.6%9.6%
Net Margin-6.8%5.5%
Balance Sheet
Total Assets$1.2B$1.4B$1.8B
Equity$673.5M$745.7M$1.3B
ROE-8.6%4.1%
Per Share
EPS-$1.77$1.47
Cash Flow
Operating CF-$158.5M$64.1M
CapEx-$17.2M$15.6M

Source: XBRL data in NOVANTA INC (NOVT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate NOVT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
NOVT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202633$2.58B
Q2 202636$2.90B
Q1 202631$1.90B
Q4 202529$1.81B
Q3 202530$1.63B
Q2 202530$2.11B
Q1 202527$1.23B
Q4 202425$1.22B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

NOVT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Nov 5, 2026--
8-KOct 2, 2026Analysis-
4Sep 15, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
8-KJul 27, 2026Analysis-
4Jul 7, 2026--
8-KJun 9, 2026Analysis
8-KJun 9, 2026Analysis
4Jun 4, 2026-
8-KMay 29, 2026Analysis
8-KMay 15, 2026Analysis
10-QMay 11, 2026Analysis
8-KMay 11, 2026Analysis
4May 7, 2026-
SC 13GApr 30, 2026-
SC 13GApr 29, 2026-
4Apr 21, 2026--
4Mar 18, 2026--
4Mar 4, 2026--
4Feb 26, 2026--
4Feb 26, 2026--
4Feb 26, 2026--

Related Information Technology companies

All Information Technology →

NOVT SEC filings: frequently asked questions

Are NOVT insiders buying or selling?

In the last 90 days, NOVANTA INC (NOVT) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $97,859 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold NOVT stock?

As of September 30, 2026, the largest NOVANTA INC (NOVT) holders among the 13F filers tracked by SignalX were BlackRock ($701.2 million), Vanguard Portfolio Management LLC ($343.3 million), T. Rowe Price Group ($292.2 million), Vanguard Capital Management LLC ($241.3 million), State Street Corp ($210.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was NOVT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), NOVANTA INC (NOVT) reported revenue of $980.6 million (up 3.3% from FY2024) and net income of $53.8 million. Diluted EPS was $1.47. The figures come from the XBRL data in the 10-K.

What are the main risks in NOVT's latest 10-K?

In the 10-K filed February 23, 2026, NOVANTA INC (NOVT) flagged: Regulatory/legal risk: Restrictions on dividends and asset transfers from foreign subsidiaries under local laws impacting funding for parent operations. Geopolitical/macro risk: $67.6M cash and $74M debt held by non-North American subsidiaries, limiting capital repatriation flexibility. (AI summary of the Risk Factors section.)

What did NOVT report in its latest 8-K?

NOVANTA INC (NOVT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Novanta announced fiscal Q3 2026 financial results for the quarter ended October 2, 2026.

What are the latest NOVT SEC filings?

NOVANTA INC (NOVT) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 5, 2026.

What is NOVT's SEC CIK number?

NOVANTA INC (NOVT)'s SEC Central Index Key (CIK) is 1076930. EDGAR lists every NOVT filing under that number.

Ask anything about NOVT

The research agent reads NOVT's filings, financials, insider trades and 13F holders, then answers with sources.